About Mirxes
Mirxes is a company based in Singapore (Singapore) founded in 2014. Mirxes has raised $254 million across 5 funding rounds from investors including Mitsui & Co, Charoen Pokphand Group and EDBI. The company has 352 employees as of December 31, 2024. Mirxes offers products and services including GASTROClear, LUNGClear, Fortitude 2.1, APEX Tissue, and ID3EAL Suite. Mirxes operates in a competitive market with competitors including UDX and Liquid Mine, among others.
- Headquarter Singapore, Singapore
- Employees 352 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mirxes Holding Company Limited
-
Annual Revenue
$20.38 M (USD)-16.41as on Dec 31, 2024
-
Net Profit
-$92.76 M (USD)-32.93as on Dec 31, 2024
-
EBITDA
-$63.98 M (USD)-35.01as on Dec 31, 2024
-
Total Equity Funding
$254 M (USD)
in 5 rounds
-
Latest Funding Round
$50 M (USD), Series D
Jul 26, 2023
-
Investors
Mitsui & Co.
& 11 more
-
Employee Count
352
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mirxes
Mirxes is a publicly listed company on the HKEX with ticker symbol 2629 in Hong Kong, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mirxes
Mirxes offers a comprehensive portfolio of products and services, including GASTROClear, LUNGClear, Fortitude 2.1, APEX Tissue, and ID3EAL Suite.
Blood-based test for early gastric cancer detection
Test for early lung cancer identification
Diagnostic panel for syndromic infectious disease testing
Tool for cancer treatment selection and sequencing
Platform for miRNA knowledge and research applications
People of Mirxes
Unlock access to complete
Unlock access to complete
Funding Insights of Mirxes
Mirxes has successfully raised a total of $254M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $50 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mirxes
Mirxes has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Mitsui & Co, Charoen Pokphand Group and EDBI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked |
Investor details for Mirxes
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mirxes
Investment portfolio details for Mirxes
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mirxes
Detailed financials for Mirxes
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mirxes Comparisons
Peer comparison for Mirxes
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mirxes
Mirxes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as UDX and Liquid Mine, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-invasive blood-based diagnostics for early cancer detection are developed.
|
|
| Locked | Locked | Locked |
Developer of monitoring test system for early detection of leukemia recurrence
|
Detailed competitors of Mirxes
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mirxes
Complete news archive for Mirxes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mirxes
Mirxes was founded in 2014 and raised its 1st funding round 2 years after it was founded.
Mirxes is headquartered in Singapore, Singapore.
Mirxes is a funded company, having raised a total of $254M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Mirxes is 352.
Annual revenue of Mirxes is $20.38M as on Dec 31, 2024.
Developer of miRNA-based test for the detection of cancer. The companys core technology is a highly specific RT-PCR primer that imposes a conformational restriction on miRNA for efficient binding to mature, but not precursor miRNAs, coupled with optimized RT-PCR reagents. These primers confer high specificity, sensitivity, and enhanced signal-to-noise ratio in amplification reactions. The company manufactures miRNA detection and quantification kits for research and is developing miRNA-based liquid biopsy kits for gastric cancer, lung cancer, and breast cancer detection.
Mirxes's top competitors include UDX and Liquid Mine.
Mirxes offers GASTROClear, LUNGClear, Fortitude 2.1, APEX Tissue, and ID3EAL Suite.
Yes, Mirxes is publicly traded on HKEX under the ticker symbol 2629.
Mirxes has 12 investors. Key investors include Mitsui & Co, Charoen Pokphand Group, EDBI, NHH Ventures, and Rock Springs Capital.
The ticker symbol of Mirxes is 2629 on HKEX.
The valuation of Mirxes is $500M as of Jul 2021.